One of the most significant frontiers in nasal spray technology is the "Nose-to-Brain" pathway. This route utilizes the olfactory and trigeminal nerve pathways to bypass the "Blood-Brain Barrier" (BBB), allowing for the direct delivery of therapeutic agents to the Central Nervous System (CNS). This is particularly vital for treating conditions like migraine, cluster headaches, and acute psychiatric crises where rapid brain penetration is required.

Recent 2024–2025 clinical trends have seen the rise of intranasal Esketamine for treatment-resistant depression and nasal formulations for seizure rescue. To explore the clinical trial data and the development of "Precision Olfactory Delivery" (POD) devices, refer to the Nasal Spray Market resource. These devices are designed to target the "Olfactory Region" at the very top of the nasal cavity, a difficult-to-reach area that provides the most direct link to the cerebrospinal fluid.